Abstract
Drug development is a long and expensive process. It starts from the identification of a small molecule (hit compound) endowed with the ability to suppress a cellular or viral enzyme essential for the development of a given disease and proceeds through subsequent rounds of structural changes and optimization until the desired pharmacological properties are reached (lead compound). At any point of the hit-to-lead optimization process, it is of essence to monitor the behavior of the intermediate molecules with respect to their molecular targets. This involves precise mechanism of action studies as well as quantitative measurement of the performance of the compound against its target. Enzyme kinetic studies are thus an essential component of the drug development process. Relevant examples of the power of enzyme kinetics in the antiviral drug development process will be discussed in the context of anti-HIV chemotherapy.
Keywords: Enzyme kinetics, Virtual screening, SAR, Inhibitors, Antiviral drugs.
Current Pharmaceutical Biotechnology
Title:The Power of Enzyme Kinetics in the Drug Development Process
Volume: 14 Issue: 5
Author(s): Alberta Samuele, Emmanuele Crespan, Anna Garbelli, Laura Bavagnoli and Giovanni Maga
Affiliation:
Keywords: Enzyme kinetics, Virtual screening, SAR, Inhibitors, Antiviral drugs.
Abstract: Drug development is a long and expensive process. It starts from the identification of a small molecule (hit compound) endowed with the ability to suppress a cellular or viral enzyme essential for the development of a given disease and proceeds through subsequent rounds of structural changes and optimization until the desired pharmacological properties are reached (lead compound). At any point of the hit-to-lead optimization process, it is of essence to monitor the behavior of the intermediate molecules with respect to their molecular targets. This involves precise mechanism of action studies as well as quantitative measurement of the performance of the compound against its target. Enzyme kinetic studies are thus an essential component of the drug development process. Relevant examples of the power of enzyme kinetics in the antiviral drug development process will be discussed in the context of anti-HIV chemotherapy.
Export Options
About this article
Cite this article as:
Samuele Alberta, Crespan Emmanuele, Garbelli Anna, Bavagnoli Laura and Maga Giovanni, The Power of Enzyme Kinetics in the Drug Development Process, Current Pharmaceutical Biotechnology 2013; 14 (5) . https://dx.doi.org/10.2174/138920101405131111105023
DOI https://dx.doi.org/10.2174/138920101405131111105023 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Squamous Cell Gallbladder Carcinoma: A Case Report and Literature Review
New Emirates Medical Journal The Influence of Ageing and Gender in Musculoskeletal Stem Cell
Current Stem Cell Research & Therapy The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Microarray-Based Technology for Glycomics Analysis
Combinatorial Chemistry & High Throughput Screening Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Editorial [Hot Topic: Towards Tailored Treatment - New Organ-Specific Drug Strategies Interfering in Signal Transduction (Guest Editors: Jai Prakash and Martin H. de Borst)]
Current Signal Transduction Therapy Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews Recent Advances in Intervention in Markovian Regulatory Networks
Current Genomics Key Roles of MicroRNA-22 Family in Complex Organisms Inferred from its Evolution
MicroRNA Vertical and Horizontal Convergences of Targeting Pathways in Combination Therapy with Baicalin and Jasminoidin for Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Exploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo
Current Organic Chemistry NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays
Anti-Cancer Agents in Medicinal Chemistry Polyethylenimine as a Promising Vector for Targeted siRNA Delivery
Current Clinical Pharmacology Estrogen Regulation of MicroRNA Expression
Current Genomics Role of Dendritic Cells in HIV-Immunotherapy
Current HIV Research Acknowledgements to Reviewers:
Recent Patents on Anti-Cancer Drug Discovery